Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 7/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.41 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 12/20 | 0.41 |
| ▸ | HTR2A | P28223 | 12/20 | 0.41 |
| ▸ | DRD3 | P35462 | 12/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699401 | 1.00 | SLC9A1 (0.52) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL6678123 | 1.00 | SLC9A1 (0.52) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL6680606 | 0.90 | SLC9A1 (0.43) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL6680609 | 0.90 | SLC9A1 (0.43) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL17899786 | 0.81 | SLC9A1 (0.52) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL17894548 | 0.81 | SLC9A1 (0.52) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL17894547 | 0.81 | SLC9A1 (0.52) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL19699402 | 0.81 | SLC9A1 (0.52) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL8489071 | 0.81 | SLC9A1 (0.53) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL6681536 | 0.80 | KDM4E (0.41) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382883-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. | 2023-11-30 | — | — | US | disclosed |
| US-11760740-B2 | Highly purified pharmaceutical grade tasimelteon | VANDA PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| EP-4223747-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | Vanda Pharmaceuticals Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230150964-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. | 2023-05-18 | — | — | US | disclosed |
| US-11566011-B2 | Highly purified pharmaceutical grade tasimelteon | VANDA PHARMACEUTICALS INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11203581-B2 | Highly purified pharmaceutical grade tasimelteon | VANDA PHARMACEUTICALS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210017143-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. | 2021-01-21 | — | — | US | disclosed |
| US-10829465-B2 | Highly purified pharmaceutical grade tasimelteon | VANDA PHARMACEUTICALS INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200190048-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. | 2020-06-18 | — | — | US | disclosed |
| US-10611744-B2 | Highly purified pharmaceutical grade tasimelteon | VANDA PHARMACEUTICALS INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20170190683-A1 | HIGHLY PURIFID PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. | 2017-07-06 | — | — | US | disclosed |
| WO-2016109359-A1 | CYCLOPROPYL DIHYDROBENZOFURAN MODULATORS OF MELATONIN RECEPTORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109359-A1 | CYCLOPROPYL DIHYDROBENZOFURAN MODULATORS OF MELATONIN RECEPTORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| EP-1027043-B1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1027043-A4 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2002-02-20 | — | — | EP | disclosed |
| EP-1027043-A1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | Bristol-Myers Squibb Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6060506-A | FOR TREATMENT OF SLEEP DISORDERS, CIRCADIAN RHYTHM DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| US-5981571-A | USEFUL AS MELATONERGIC AGENTS IN THE TREATMENT OF SLEEP DISORDERS, SEASONAL DEPRESSION, SHIFTS IN CIRCADIAN CYCLES, MELANCHOLIA, STRESS, APPETITE REGULATION, BENIGN PROSTATIC HYPERPLASIA AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| US-5856529-A | ADJUSTMENT OF NERVOUS SYSTEM, ENDOCRINE FUNCTION; REPRODUCTION, BODY WEIGHT AND METABOLISM | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1998025606-A1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190048-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | GMPS, TAS2R45, TAS2R10 | SLC9A1 3196/4885MTNR1B 2331/4885SLC9A5 2407/4885 |
| US-11566011-B2 | Highly purified pharmaceutical grade tasimelteon | GMPS, TAS2R45, TAS2R10 | SLC9A1 3196/4885MTNR1B 2331/4885SLC9A5 2407/4885 |
| US-20170190683-A1 | HIGHLY PURIFID PHARMACEUTICAL GRADE TASIMELTEON | GMPS, TAS2R60, TAS2R20 | SLC9A1 3889/4885MTNR1B 3291/4885SLC9A5 3020/4885 |
| US-20210017143-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | GMPS, TAS2R45, TAS2R10 | SLC9A1 3196/4885MTNR1B 2331/4885SLC9A5 2407/4885 |
| US-20230382883-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | GMPS, TAS2R45, TAS2R10 | SLC9A1 3196/4885MTNR1B 2331/4885SLC9A5 2407/4885 |
| US-11760740-B2 | Highly purified pharmaceutical grade tasimelteon | GMPS, TAS2R45, TAS2R10 | SLC9A1 3196/4885MTNR1B 2331/4885SLC9A5 2407/4885 |
| US-11203581-B2 | Highly purified pharmaceutical grade tasimelteon | GMPS, TAS2R45, TAS2R10 | SLC9A1 3196/4885MTNR1B 2331/4885SLC9A5 2407/4885 |
| US-20230150964-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | GMPS, TAS2R45, TAS2R10 | SLC9A1 3196/4885MTNR1B 2331/4885SLC9A5 2407/4885 |
| US-10611744-B2 | Highly purified pharmaceutical grade tasimelteon | GMPS, TAS2R45, TAS2R10 | SLC9A1 3196/4885MTNR1B 2331/4885SLC9A5 2407/4885 |
| US-10829465-B2 | Highly purified pharmaceutical grade tasimelteon | GMPS, TAS2R45, TAS2R10 | SLC9A1 3196/4885MTNR1B 2331/4885SLC9A5 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.